Sotrastaurin

Overview

Sotrastaurin (AEB071) is a potent and orally-active pan- PKC inhibitor, with K i s of 0.22 nM, 0.64 nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKCθ , PKCβ , PKCα , PKCη , PKCδ and PKCε , respectively.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > MARCKS | Products > Signaling Pathways > PKC

Product Information

• Catalog No.: HY-10343
• CAS No.: 425637-18-9
• Molecular Formula: C25H22N6O2
• Molecular Weight: 438.48
• Purity: 99.79%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: 2.5 mg/mL (5.70 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source